Victory Capital Reduces Stake in Regeneron Pharmaceuticals

Institutional investor lowers position in biotech company by over 50%

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Victory Capital Management Inc. has lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.6% in the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. The fund now owns approximately 82,386 shares of the biopharmaceutical company's stock, down from 170,278 shares previously.

Why it matters

Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies. Changes in institutional ownership can signal shifts in market sentiment and investor confidence around the company's future prospects.

The details

According to the 13F filing, Victory Capital Management sold 87,892 shares of Regeneron Pharmaceuticals during the third quarter. The fund now owns roughly 0.08% of the company's outstanding stock, valued at $46.3 million as of the most recent reporting period.

  • Victory Capital Management filed its 13F report for the third quarter of 2026.

The players

Victory Capital Management Inc.

An investment management firm that provides asset management services to institutional and individual investors.

Regeneron Pharmaceuticals, Inc.

A biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Victory Capital's Regeneron position reflects broader market trends and investor sentiment around the biotech sector. While Regeneron remains a highly-rated stock, this filing suggests some institutional investors may be taking a more cautious approach to the company's outlook.